About
Telo Therapeutics develops orally bioavailable targeted protein degraders that inhibit nuclear transport proteins, aiming to treat solid and hematological cancers resistant to existing therapies.
Explore Telo Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.